Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.

Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, Smyth MJ, Lollini PL, Musiani P, Forni G, Iezzi M, Cavallo F.

J Immunol. 2014 Jun 1;192(11):5434-41. doi: 10.4049/jimmunol.1301248. Epub 2014 Apr 30.

2.

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.

Bandini S, Curcio C, Macagno M, Quaglino E, Arigoni M, Lanzardo S, Hysi A, Barutello G, Consolino L, Longo DL, Musiani P, Forni G, Iezzi M, Cavallo F.

Oncoimmunology. 2013 Sep 1;2(9):e26137. Epub 2013 Sep 12.

3.

DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis.

Olgasi C, Dentelli P, Rosso A, Iavello A, Togliatto G, Toto V, Liberatore M, Barutello G, Musiani P, Cavallo F, Brizzi MF.

Eur J Cancer. 2014 Jan;50(1):234-46. doi: 10.1016/j.ejca.2013.09.016. Epub 2013 Oct 18.

4.

HCG hastens both the development of mammary carcinoma and the metastatization of HCG/LH and ERBB-2 receptor-positive cells in mice.

Iezzi M, Quaglino E, Cappello P, Toto V, Sabatini F, Curcio C, Garotta G, Musiani P, Cavallo F.

Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):621-30.

PMID:
21978694
5.

A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters.

Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F.

Cancer Prev Res (Phila). 2011 Jul;4(7):994-1001. doi: 10.1158/1940-6207.CAPR-10-0301.

6.

The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.

Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, Tagliabue E, Pupa SM, Musiani P, Monaci P, Menard S, Amici A.

PLoS One. 2011 Apr 29;6(4):e18727. doi: 10.1371/journal.pone.0018727.

7.

Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E.

Clin Cancer Res. 2011 Mar 15;17(6):1571-81. doi: 10.1158/1078-0432.CCR-10-2804. Epub 2010 Dec 15.

8.

The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitis.

Casorelli I, Pannellini T, De Luca G, Degan P, Chiera F, Iavarone I, Giuliani A, Butera A, Boirivant M, Musiani P, Bignami M.

PLoS One. 2010 Aug 10;5(8):e12070. doi: 10.1371/journal.pone.0012070.

9.

Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.

Bono AV, Pannellini T, Liberatore M, Montironi R, Cunico SC, Cheng L, Sasso F, Musiani P, Iezzi M.

Anal Quant Cytol Histol. 2010 Jun;32(3):136-45.

PMID:
20701066
10.

Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.

Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolò C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F.

J Immunol. 2010 Jun 1;184(11):6124-32. doi: 10.4049/jimmunol.0901215. Epub 2010 Apr 30.

11.

AvidinOX for highly efficient tissue-pretargeted radionuclide therapy.

De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P.

Cancer Biother Radiopharm. 2010 Apr;25(2):143-8. doi: 10.1089/cbr.2009.0738.

PMID:
20423226
12.

Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten.

Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P, Poli V.

Cancer Res. 2010 Mar 15;70(6):2558-67. doi: 10.1158/0008-5472.CAN-09-2840. Epub 2010 Mar 9.

13.

Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene.

Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R, Poli V.

Mol Carcinog. 2010 Feb;49(2):114-20. doi: 10.1002/mc.20605.

PMID:
20027636
14.

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.

Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V.

Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.

PMID:
19903903
15.

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M.

J Cell Mol Med. 2010 Dec;14(12):2803-15. doi: 10.1111/j.1582-4934.2009.00926.x.

16.

Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.

Russo MT, De Luca G, Casorelli I, Degan P, Molatore S, Barone F, Mazzei F, Pannellini T, Musiani P, Bignami M.

Cancer Res. 2009 May 15;69(10):4372-9. doi: 10.1158/0008-5472.CAN-08-3292. Epub 2009 May 12.

17.

Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.

De Giovanni C, Nicoletti G, Landuzzi L, Croci S, Palladini A, Antognoli A, Murgo A, Ianzano ML, Grosso V, Stivani V, Iezzi M, Musiani P, Nanni P, Lollini PL.

Vaccine. 2009 Mar 23;27(14):2065-9. doi: 10.1016/j.vaccine.2009.01.113. Epub 2009 Jan 31.

PMID:
19428831
18.

The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.

Di Carlo E, D'Antuono T, Pompa P, Giuliani R, Rosini S, Stuppia L, Musiani P, Sorrentino C.

Clin Cancer Res. 2009 May 1;15(9):2979-87. doi: 10.1158/1078-0432.CCR-08-1951. Epub 2009 Apr 14.

19.

A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.

De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL.

Hum Gene Ther. 2009 May;20(5):453-64. doi: 10.1089/hum.2008.172.

PMID:
19215191
20.

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E.

Sci Signal. 2008 Sep 9;1(36):ra3. doi: 10.1126/scisignal.1161577.

21.

Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice.

Mastini C, Becker PD, Iezzi M, Curcio C, Musiani P, Forni G, Cavallo F, Guzmán CA.

Curr Cancer Drug Targets. 2008 May;8(3):230-42.

PMID:
18473736
22.

Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.

Bono AV, Montironi R, Pannellini T, Sasso F, Mirone V, Musiani P, Iezzi M.

Prostate Cancer Prostatic Dis. 2008;11(4):377-83. doi: 10.1038/pcan.2008.13. Epub 2008 Apr 1.

PMID:
18379588
23.

Systemic spread is an early step in breast cancer.

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA.

Cancer Cell. 2008 Jan;13(1):58-68. doi: 10.1016/j.ccr.2007.12.003.

24.

Antimetastatic activity of a preventive cancer vaccine.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL.

Cancer Res. 2007 Nov 15;67(22):11037-44. Erratum in: Cancer Res. 2007 Dec 15;67(24):12034.

25.

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ.

Cancer Res. 2007 Jun 1;67(11):5454-60.

26.

Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.

De Giovanni C, Croci S, Nicoletti G, Landuzzi L, Palladini A, Pannellini T, Borgia L, Iezzi M, Di Carlo E, Orengo AM, Kennedy RC, Lollini PL, Nanni P, Musiani P.

Int J Cancer. 2007 Jul 1;121(1):88-94.

27.

WIP null mice display a progressive immunological disorder that resembles Wiskott-Aldrich syndrome.

Curcio C, Pannellini T, Lanzardo S, Forni G, Musiani P, Antón IM.

J Pathol. 2007 Jan;211(1):67-75.

PMID:
17086554
28.

Triggering CD40 on endothelial cells contributes to tumor growth.

Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP.

J Exp Med. 2006 Oct 30;203(11):2441-50. Epub 2006 Oct 16.

29.

Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.

Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F.

Cancer Res. 2006 Aug 1;66(15):7734-40.

30.

A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9208-13. Epub 2006 Jun 5.

31.

Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression.

Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini PL, Forni G, Cavallo F, Musiani P.

J Immunol. 2006 Jun 15;176(12):7695-703.

32.

MicroRNA gene expression deregulation in human breast cancer.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM.

Cancer Res. 2005 Aug 15;65(16):7065-70.

33.

A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.

Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA.

Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):351-63.

PMID:
15888257
34.

The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.

Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, Hardy B, Cavallo F.

Vaccine. 2005 May 9;23(25):3280-7.

PMID:
15837233
35.

Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini PL.

Am J Pathol. 2005 Apr;166(4):1205-16.

36.

Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity.

Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo F, Forni G.

Clin Cancer Res. 2005 Mar 1;11(5):1941-52.

37.

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90. Epub 2005 Mar 7.

38.

Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.

Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S.

Cancer Res. 2005 Feb 1;65(3):1071-8.

39.

Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.

Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini PL, Cavallo F, Calogero RA.

Cancer Immunol Immunother. 2005 Jun;54(6):599-610. Epub 2005 Feb 3.

PMID:
15690207
40.

Immunobiology of her-2/neu transgenic mice.

Pannellini T, Forni G, Musiani P.

Breast Dis. 2004;20:33-42. Review.

PMID:
15687705
41.

Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.

Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F.

J Pathol. 2005 Jan;205(1):82-91.

PMID:
15586367
42.

Immunological prevention of a multigene cancer syndrome.

Croci S, Nicoletti G, Landuzzi L, De Giovanni C, Astolfi A, Marini C, Di Carlo E, Musiani P, Forni G, Nanni P, Lollini PL.

Cancer Res. 2004 Nov 15;64(22):8428-34.

43.

Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.

Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P.

Int J Cancer. 2005 Jan 1;113(1):67-77.

44.

Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent.

Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini PL.

J Immunol. 2004 Aug 15;173(4):2288-96.

45.

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.

De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, Musiani P, Cavallo F, Nanni P, Lollini PL.

Cancer Res. 2004 Jun 1;64(11):4001-9.

46.

The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis.

Pannellini T, Iezzi M, Di Carlo E, Eleuterio E, Coletti A, Modesti A, Rosini S, Neri M, Musiani P.

Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):171-80.

PMID:
15171818
47.

Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice.

Calogero RA, Musiani P, Forni G, Cavallo F.

Cell Cycle. 2004 Jun;3(6):704-6. Epub 2004 Jun 19. Review.

PMID:
15153804
48.

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F.

Cancer Res. 2004 Apr 15;64(8):2858-64.

49.

Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis.

Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, Musiani P, Poli V.

Cytokine. 2004 Apr 21;26(2):45-56.

PMID:
15050604
50.

Supplemental Content

Loading ...
Support Center